Home / Transcripts / Coherus Oncology, Inc. (CHRS) · March 9, 2026

Coherus Oncology, Inc. (CHRS) Earnings Call Transcript

March 9, 2026

NASDAQ US Health Care Biotechnology earnings 58 min

Earnings Call Speaker Segments

Carrie Graham executive
#1

Thanks, Heidi. Good afternoon, everyone, and welcome to the Coherus Oncology call covering our fourth quarter and 2025 year-end earnings. Here with me to go over our results are Denny Lanfear, our Chief Executive Officer; Dr. Theresa Lavallee, Chief Scientific and Development Officer; Dr. Rosh Dias, Chief Medical Officer; Sameer Goregaoker, Chief Commercial Officer; and Bryan McMichael, Chief Financial Officer. Before we begin, please note that this call contains forward-looking statements about what Coherus currently expects regarding future events. Actual results could differ materially, and we assume no obligation to update or revise any forward-looking statements. For additional details on risks and uncertainties, please refer to the press release we issued today and our annual report on Form 10-K. I'll now hand the call over to Denny.

Dennis Lanfear executive
#2

Thank you, Carrie, and I'm glad all of you could join for the fourth-quarter 2025 call as well as our yearly update to investors for 2025. Over this past year, we completed our strategic makeover into an oncology innovator whose focus is on defeating immune resistance in cancer. That pivot started back in September 2023, when Surface Oncology was acquired by us; through that transaction we gained two exceptionally promising candidates: tagmokitug, a CCR8 Treg cell depleter with potential to be best-in-class, along with casdozokitug, an anti-IL-27 inhibitor that is first-in-class. Over approximately the next 18 months, we managed to sell off our biosimilar business, which added $250 million to the balance sheet, reduced our secured and convertible debt of $480 million by over 90%, leaving $38.8 million, and lowered both our workforce and our costs, giving the company a much sharper focus. We used what we'd already accomplished as a foundation, and we expanded both our team and our board of directors so we could fulfill the new mission. In addition, we started a clinical development program that is elegant and efficient, covering pipeline products used alongside LOQTORZI and products from our partners, which could make it possible to begin a registration trial in 2027. Our Chief Medical Officer, Dr. Rosh Dias, will walk you through the specifics of our clinical strategy and how far we've gotten. Also in 2024, we brought to market LOQTORZI, our first commercial product in innovative oncology — a next-gen PD-1 inhibitor, and the sole approved product available in the U.S. for recurrent, locally advanced or metastatic Nasopharyngeal Carcinoma, representing a $250 million addressable market. We've undergone a really fast shift in how we approach products, how we develop things, and how we structure deals. Here's a way to think strategically about where this company is headed. Starting with our approach to finances: LOQTORZI serves a dual foundational purpose — it brings in revenue on its own in the NPC setting, and it amplifies revenue when used in combination with the assets in our pipeline. In my view, what sets Coherus apart from other small clinical-stage biotechs is that we hold a commercial product whose sales are climbing in a rare disease area where no FDA-approved rival treatments appear to be coming, backed by exceptional six-year survival results, and we sit at the highest position within the NCCN guidelines for recurrent metastatic NPC. That's why we feel good about where LOQTORZI is headed. My colleagues can confirm that sales for LOQTORZI in 2025 were over twice what they were in 2024. We view LOQTORZI as a dependable, expanding source of revenue that doesn't dilute shareholders, and as a way to fund operations while we move the promising pipeline forward, with its worth rising as we go. That's what it's really there for. Under the path we expect, we hit peak market share at some point in 2028, which works out to $175 million in annualized revenues, or roughly 70% of the $250 million total market. Sameer Goregaoker, our Chief Commercial Officer, is going to share more on that shortly. Let me offer a few important points. To start with, $175 million in annual revenue might look unassuming, yet it matters a great deal to us, since that sum comfortably covers our core burn and our entire headcount — leaving out development costs and other peripheral items such as stock option expense. Next, at some point along the way, when quarterly sales reach roughly $15 million or $16 million, the commercial push will have covered its own costs and begun helping to absorb the company's total SG&A. Our expectation is that this occurs at some point during 2026. Finally, when we get to somewhere around $30 million to $35 million each quarter, those revenues will cover our core burn — which excludes clinical trial expense, since such costs are somewhat elastic and discretionary; our expectation is that this occurs at some point during 2027. We recently brought in approximately $50 million, which encompassed backing for the commercial push, allowing us to reach that $175 million run rate sooner. In addition, we judged it strategically wise to put further money into the tagmokitug clinical program, given that the Treg space grows more competitive, with data readouts anticipated from other parties during this year. Taking the latest fundraising into account in our planning, we're confident we have enough capital to cover the important launches through 2026 and continuing into 2027. Bryan McMichael, our Chief Financial Officer, will share more details shortly. Now, onto what we're doing with our products. In addition to LOQTORZI, we have two candidates that are strongly positioned, and both have generated encouraging results in early-stage trials. Their distinct advantages give investors a way to spread risk; first, tagmokitug looks like it could be a top option in a crowded field, with wide potential therapeutic use and highly encouraging biology. Shortly, Dr. Lavallee will walk you through further scientific details regarding how it works and factors around combining it with other treatments. Since the range of possible uses is so wide, we need to run clinical studies at earlier stages and across a larger scope. A number of trials are already in motion. Our plan is to capture that broad potential not only through combinations we own, but also through alliances with partners. What we're aiming for is to become the go-to Treg depleter across every cancer therapy and treatment modality. On top of that, we see casdozokitug as the sole agent in its class, backed by striking translational findings that are tightly aimed at cancers in organs like the liver and the lung. Matching those findings, casdozokitug produced very long-lasting complete responses in first-line hepatocellular carcinoma. A follow-up study is now running. Dr. Dias will walk you through that later. Finally, I'd like to cover the deals. When it comes to strategic deals — acquisitions, divestitures, and partnerships on products — Coherus has built a solid record of delivering value for investors. That proven capability, in our view, is what unlocks hidden value, opens new markets, and generates therapeutic and worldwide synergies. Take the J&J collaboration, for instance — it matters for several reasons. To start, it represents the first proof of our aim to become the preferred Treg depleter across a wide range of companies and treatment approaches. Additional relationships along these lines are being developed. Next, it demonstrates the strength of our science and the robustness of the asset itself. And third, it demonstrates that the strategy we've built can actually be carried out and has the potential to add value for shareholders. As you're aware, we hold rights to tagmokitug and casdozokitug on a global basis, and we're eager for partnership opportunities outside the U.S. as data readouts come in during this year and the next. In our view, it's fair to anticipate that those partners would offer upfront payments and cover their portion, helping substantially to offset the costs of pivotal or registration trials, since they'd bear the expenses for patients in their own territories. That leaves us with a minority portion of the total costs, which we believe will be manageable. To wrap up, allow me to give you a summary. Across roughly the last 18 months, we've achieved considerable progress in assembling a plan that's highly executable, made up of integrated financial, product, and transaction strategies, which puts us in position to deliver meaningful investor value accretion. I'll now hand the call to Dr. Theresa Lavallee, our Chief Scientific and Development Officer, who will share deeper insights on using T-regulatory cell depletion as a therapeutic approach to overcome immune resistance in cancer. Theresa?

Theresa Lavallee executive
#3

Thanks, Denny. And good afternoon to everybody. What I'll focus on today is tagmokitug, which is a potent and selective cytolytic antibody aimed at CCR8, and I'll talk about its mechanism plus the therapeutic promise it could offer. Some background first: T-regulatory cells, or Tregs, are a cell type whose significance in treating cancer is gaining wider and wider recognition. Tumors exploit Tregs to evade the immune system, and as a result, cancer growth along with metastasis gets promoted. Across a broad variety of tumor types — including cancers of the head and neck, lung, breast, colon, prostate, and stomach — higher Treg levels are tightly linked with poor prognosis. There's a further problem with Tregs too: besides correlating with poor prognosis, they may also get upregulated whenever anti-cancer therapies are administered. I raise this because medicines that can deplete Tregs could enhance outcomes for patients on many different anti-cancer treatments. Tagmokitug's target is CCR8, which is preferentially expressed by tumors' Tregs. Not long ago we issued a publication describing tagmokitug's pharmacology as well as its molecular cancer therapeutics. In the clinic, what tagmokitug has shown us is that the treatment causes 2 key changes to the tumor's immune composition. Number one is selective and significant depletion of CCR8 positive Tregs inside tumors. Number two is an enormous increase in CD8 T cells; together, these findings suggest tagmokitug at the same time eliminates the suppressor cell in tumors while driving a rise in T cells that can kill cancer cells. Even so, the CCR8 drug class has shown limited single agent activity, which raises the question: what must these T cells have in order to become activated and kill the tumor? We are exploring 2 distinct strategies for activating T cells. One way to activate killer T cells involves PD-1 antibodies. Over the past 10 years of using such drugs, we've learned that the way PD-1 inhibitors work is by reinvigorating T cells that had already tried attacking the tumor but have since turned exhausted. We're trying to determine whether the T cells found in tumors following tagmokitug treatment are antigen-experienced exhausted T cells or possibly naive T cells. Rosh will share more detail about our tagmokitug clinical studies testing treatment alongside toripalimab, our PD-1 antibody. Findings from our phase I study include a partial response in a fourth-line head and neck cancer patient who had progressed on earlier PD-1 therapy. Since adding tagmokitug to toripalimab restored a response that had previously failed PD-1, this exciting data demonstrated that CCR8 positive Tregs were a primary mechanism of resistance. Our ongoing expansion cohort in head and neck cancer is meant to answer whether CCR8 positive Tregs are a primary PD-1 resistance mechanism in this second-line patient population. The other strategy we're investigating for T cell activation after tagmokitug treatment is direct activation of the T cell receptor complex by mimicking a protein known as CD3; that allows for activation of naive T cells. This program is supported by an investment of approximately $30 million-$35 million per quarter. A large number of T cell engagers—TCEs—are bispecific antibodies. One arm attaches to a protein on the tumor, while the other arm attaches to CD3 on T cells. By redirecting T cells to destroy the tumor, TCEs perform effectively against blood cancers, but until now their results in solid tumors have been only modest. Based on what the data show, two main issues in solid tumors lead to restricted TCE activity. The first issue: T cells appear sparsely inside those tumors, which prevents the molecule from positioning the tumor and the T cell near one another. The second issue: Tregs exist there and get activated, and that dampens the T cell response. We're pleased to have announced our deal with Johnson & Johnson to study a combination of tagmokitug—an antibody that removes Tregs—together with pasritamig, a prostate-specific TCE that attaches to KLK2 on prostate tumors. As this combination trial advances, tagmokitug turns into the initial CCR8 antibody in prostate cancer and also the initial CCR8 antibody paired with a TCE. Coherus Oncology continues to drive the science forward for the CCR8 drug class. As I mentioned earlier, Tregs are known to hold back cancer therapy, and tagmokitug has by now shown itself to be a targeted therapeutic strategy that can deplete Tregs and rebalance immunity by increasing T cells inside tumors. Crucially, all immune activating agents—immune checkpoint inhibitors like PD-1 inhibitors and TCEs—increase Treg counts in tumors, and so do the majority of anti-cancer treatments. Take, for example, a study published recently showing that androgen receptor deprivation therapy increases Tregs in prostate cancer, while many scientific reports show that radiation, chemotherapy, targeted therapies, and angiogenesis inhibitors similarly increase Tregs in tumors, and this correlates with poorer patient outcomes. Our view is that tagmokitug holds wide potential for use together with other therapies as a cancer treatment, and we're thrilled that the pasritamig/tagmokitug combination is the first one involving a partner company. And of course, we continue pursuing novel combinations with additional partners. With that, I'll pass things to Dr. Dias, who will go into the clinical development in more detail. Rosh?

Rosh Dias executive
#4

Thank you, Theresa, and good afternoon to all of you. I'm happy about the ongoing advancement of our clinical development program spanning multiple regions, covering both tagmokitug and casdozokitug. The programs for these two molecules tackle conditions where medical needs are clearly unmet, using studies designed very deliberately, and they rest on solid scientific and clinical justification. As we've said before, we're still on schedule for the first data readouts starting in mid-'26. Now I'd like to spend a few minutes walking through each program on its own. Starting with tagmokitug, our extremely selective CCR8 cytolytic antibody, for which we're right now conducting two protocols under what we call the TregCheck program. The initial protocol, in a second-line head and neck squamous cell population, is built on the compelling data we shared at AACR 2025, where our findings showed obvious tumor remodeling from Tagmo given as monotherapy, with CCR8-positive Tregs being depleted, along with a substantial rise in CD8 positive T-cells, matching a far more cytotoxic tumor microenvironment. As you just heard, combining agents helps these ingressed T-cells become activated. In that same study, once Toripalimab was introduced, we observed a partial response in a fourth-line head and neck squamous cell patient who had been refractory to earlier PD-1 therapy. Our present head and neck squamous cell strategy evaluates 40 patients across 2 doses of Tagmo combined with Tori and poses the question of whether Tagmo can reverse PD-L1 resistance in the second-line population; we still expect initial data around the middle of '26. Our second protocol is an umbrella protocol covering 4 targeted tumor types in cohorts A to D, which include second-line upper GI adenocarcinoma, second-line ESCC, first-line ESCC, and fourth-line plus colorectal carcinoma, in that order. The upper GI adeno cohort is a second-line cohort, encompassing gastric adeno, GEJ, and esophageal adenocarcinoma, and it likewise broadly asks whether Tagmo can reverse PD-L1 resistance. As a reminder, this tumor type has demonstrated proof of principle for the class, with Lenova Medicine presenting data at ASCO 2024 for their CCR8 combined with our PD-1 inhibitor, Tori, showing an encouraging overall response rate in a second-line plus gastric population. Our upper GI adeno cohort evaluates 2 doses of Tagmo together with Tori in 40 subjects. Once again, we still expect early data around the middle of this year. Our esophageal squamous cell cohorts leverage Tori's activity regardless of PD-L1 levels, which is perhaps most pronounced in this tumor type and which underlies Tori's approval as the only EU-approved PD-1 for esophageal squamous cell irrespective of PD-L1 status. Cohort B is a second-line esophageal cohort using two doses of Tagmo combined with Tori. Cohort C examines a first-line esophageal population with Tagmo given together with both Tori and chemo, with the explicit goal of generating safety data alongside chemo, which might let us explore earlier treatment paradigms. We expect data during the second half of this year for these two cohorts. Cohort D is examining Tagmo alongside Tori within the fourth-line plus colorectal carcinoma population — a condition that represents a growing public health concern, especially among younger people. Just to remind everyone, the CCR8 space has demonstrated some responses in CRC, and our strategy involves looking at 20 patients, initially concentrating on the non-liver-met group before advancing into the liver-met group. Enrollment for the CRC cohort began in the second half of last year, and we expect early data late this year, or possibly as soon as early '27. We're extremely enthusiastic about launching the tagmokitug pasritamig combination cohort, which, as Theresa mentioned, is both the first TCE CCR8 combination study and the first in CRPC, and it's a highly rational pairing given how both agents work mechanistically; this pairing is intended to build on the pasritamig data presented at ASCO 2025, which showed an encouraging PSA50 in a late-line metastatic castration-resistant prostate cancer population, supporting progress into pivotal studies. Metastatic CRPC is regarded as an immunologically cold tumor, with few treatment choices remaining once patients reach later lines of therapy. Our initial strategy will target a third-line plus population, evaluating a safety cohort and additional PSA50 endpoints, which we expect to begin in the second half of this year. Now turning to Casdozokitug, our first-in-class antibody directed at IL-27, a context-dependent immunosuppressive cytokine that is particularly relevant in tumors like Hepatocellular Carcinoma and non-small cell lung cancer. Our recently named Catalyze program is focused initially on first-line HCC and builds on the highly encouraging data presented at ASCO GI 2025, where we showed that adding Casdozo to the existing standard of care, Atezo and Bev, yielded a 38% overall response rate and, perhaps more significantly, a complete response rate of 17%, both of which compare quite favorably against historical benchmarks, with activity regardless of etiology and strong durability of response alongside a favorable safety profile. Our current ongoing study replaces Atezo with our PD-1 Tori and enrolls 72 patients across 3 arms. Those are 2 dose levels of Casdozo combined with Tori Bev versus Tori Bev alone, and it's designed with 3 objectives. First, to further characterize efficacy and safety, and also to address the FDA's Project Optimus and address contribution of components as we advance along the development pathway; this trial continues to accrue well globally, and we remain on track for initial data around mid-year '26. As a reminder, the earlier study showed an increase in response rate and a deepening of response over time, so we do anticipate the same from the ongoing program. To sum up, our TregCheck program with Tagmo across several targeted cohorts is meant to tell us in which of these specific tumor types we might see a signal worth taking forward into broader programs. Our Catalyze program with Casdozokitug is asking whether we can improve upon the current standard of care by adding Casdozokitug. Two main factors decide precisely when the data will be available. The first is how many patients have been enrolled in the study. The second is how many scans might be needed to demonstrate activity, and that will vary from one program to another. We are still on schedule to present initial data around the middle of 2026 and afterward, and we'll keep giving updates as things move forward. With that, I'll pass things to Sameer. Sameer?

Sameer Goregaoker executive
#5

Thanks, Rosh. We're glad to share that LOQTORZI net revenue climbed to $40.8 million across full year 2025, compared with $19.1 million in 2024 — that works out to 113% growth year-over-year. As we've mentioned before, looking ahead we anticipate demand rising on average 10% to 15% each quarter versus the prior one. Just like in 2025, individual quarters will show some unevenness because of patient flow and other variables; in Q4, net revenue came in at $12.4 million, which was 11% growth over Q3. We recorded robust quarter-over-quarter demand growth of 15.5% during Q4. The gap between net revenue and demand growth came from wholesaler inventory declines in Q4 relative to Q3. Demand growth was driven by new patients beginning treatment at both newly acquired and established accounts, and the number of purchasing accounts climbed 11%, a sign that usage is broadening out. We're happy with that 2025 growth, but there's still a lot of room left, especially in the community segment, where chemo-only use and off-label IO persist. As you may recall, late in 2024 the NCCN guidelines for NPC were revised, making LOQTORZI the only preferred option for recurrent and metastatic NPC. In 2025, those guidelines served as a catalyst for LOQTORZI's growth, and we remain focused on advancing education about the guidelines and about our superior overall survival relative to chemotherapy by itself. This brings me to the thrilling, paradigm-shifting six-year overall survival results that were shared at ESMO Asia back in December. According to these findings, individuals receiving LOQTORZI alongside chemotherapy survive for roughly 65 months — more than five years. In comparison, those given only chemo pass away in under three years. That works out to an extra two and a half years of survival advantage for people treated with LOQTORZI. On the basis of these results, our view is that nobody ought to get chemotherapy by itself when being treated for NPC — a position that the overwhelming majority of KOLs also hold. So our main priority is to make sure every targeted oncologist learns about this fresh survival information; we are doing everything possible to put these paradigm-shifting findings before physicians. Right now, our sales force has completed all of its training and is actively working to inform doctors. When it comes to multi-channel efforts, we're pursuing several different tactics at once — things like educational videos featuring KOLs, brief messages, and emails going out to the physicians we're targeting. Beyond that, we're putting substantial money into CRM technology platforms and improvements to our data so that advanced analytics can strengthen how we execute in rare disease; the amount we're spending to acquire extra claims data and patient alerts data has been doubled. Thanks to this, we can see close to 70% of all claims across the U.S., and that information lets our sales team receive alerts about patient opportunities as they happen in real time. We've also grown our field footprint so that we can connect with a greater number of physicians. Our field reps are concentrating on tier one, or high-value, targets. But since NPC is a rare disease, a patient could show up at just about any oncology practice nationwide. So we're widening our coverage by bringing a remote sales force online; those reps will call on tier two physicians, leaving the field team free to pursue tier one targets. There's also a sizable NPC opening inside Veterans Affairs hospitals. Getting into VA hospitals is usually tough, so we've engaged a dedicated set of contract representatives, and each of them comes with extensive experience selling into the VA. In short, our confidence remains intact that we'll achieve our goal of capturing a leading share of the NPC market, with peak share expected in 2028. Because the six-year long-term results showed such a meaningful survival advantage, everyone on our commercial side remains committed to ensuring patients don't miss the opportunity for a longer life with LOQTORZI. At this point, I'll turn things over to our Chief Financial Officer, Bryan McMichael.

Bryan McMichael executive
#6

Thanks, Sameer, and good afternoon to all of you. I'll begin by walking through where the company stood financially as of the close of the year, along with our Q4 results. Then I'll share a bit more detail on how the balance sheet has changed and offer some perspective looking ahead. As Denny noted, across 2024 and 2025 we brought down the principal owed on our term and convertible debt by more than 90%, from a peak of $480 million to $38.8 million at the close of 2025. That drove a meaningful drop in interest expense, which I'll get into later, and it also pushed our earliest debt maturity out to May 2029. Our headcount went from roughly 228 at the finish of 2024 to roughly 147 at the finish of 2025 — a reduction of approximately 35%. Among the biggest Q4 changes was the decrease in legacy liabilities tied to the divested businesses. To be specific, accrued rebates, fees, and reserves — mostly made up of legacy product liabilities — came to $30 million as of December 31. That's under half the $67 million balance from just one quarter before. Moving commercial contracts over to a court was essentially done by the time Q4 began. That set the wind down of TSA assets and liabilities in motion. Nearly all the TSA receivables were collected during Q4, taking that balance from $241 million when the quarter started to under $1 million by year-end. The cash we collected has gone toward lowering TSA liabilities, from $254 million at the beginning of Q4 down to $65 million at year-end. We anticipate the rest of these legacy business liabilities will be paid down over the coming quarters in a front-weighted manner; beyond that, let me also remind you that we stand to receive 2 earn-out sales milestones worth $37.5 million apiece. Earning those milestones depends on 4 consecutive quarters of UDENYCA sales beginning in Q3 2025. That means $300 million within 5 quarters, or through Q3 2026, for the first $37.5 million milestone, and $350 million within 7 quarters, or through Q1 2027, for the second one. With 2 quarters of sales behind us relative to the earn-out term, we feel we're well positioned to collect these payments and will keep you updated. Sameer went through in detail the year-over-year growth in LOQTORZI net revenues and the extra investments in commercial infrastructure we're making to grow sales. We plan to give full year 2026 revenue guidance on our earnings call in August. Now let me move to OpEx. Q4 came in largely consistent with the trends we saw across 2025. To be specific, SG&A expenses from continuing operations fell to $23.6 million, down from $29.6 million in Q4 of last year. Worth noting: this marks the fourth quarter in a row that these expenses were flat or lower, as we finished transforming the business. The declines stem mainly from fewer employees, leaving biosimilars, and disciplined spending. R&D expenses from continuing operations in Q4 reached $31 million, versus $20.8 million in Q4 2024. Unlike what we saw with SG&A, spending on R&D ticked up a bit each quarter during 2025, reflecting our commitment to Coherus's encouraging pipeline. Naturally, paying down debt brought about a meaningful decrease in the cash we spent on interest. That figure covers borrowings shown in continuing as well as discontinued operations, totaling $9.9 million for 2025; it represents more than $15 million in savings compared with the $25.4 million we paid in 2024, highlighting what the debt paydowns across 2024 and 2025 have delivered. At year-end, our cash equivalents and investments stood at $172.1 million. As everyone knows, we raised capital recently, among which was a $50 million follow-on offering during last month. Uses for that money begin with investments backing the substantial upside potential of the pipeline. That covers added indications for tagmokitug, since Treg depletion has become a highly significant MOA in treating cancer. Fresh illustrations are our phase IIa CRC study and the expected launch of the combination study alongside J&J in metastatic prostate cancer. We're also putting more money into our commercial footprint and capabilities so we can chase the $250 million commercial opportunity that LOQTORZI and NPC present, which Sameer walked through. He explained that rising LOQTORZI sales will increasingly cover costs as the years go by. To give a bit more detail, when our commercial effort pays for itself, we mean LOQTORZI sales will cover costs, royalties, and the sales force's cash costs. When revenues cover c-core burn, we're talking about those commercial efforts along with other cash costs apart from anything tied directly to clinical trials. With that, I'll turn the call back to Denny.

Dennis Lanfear executive
#7

Thanks, Brian. We feel good about what we accomplished in 2025 — we doubled LOQTORZI sales and finished our shift from a biosimilar business into an innovative oncology company centered on beating immune resistance in cancer. It's especially satisfying that during that same period, we cut total debt by more than 90% from its 2024 high, down to only $38.8 million as 2025 came to a close. Today we sit in a strong strategic position: revenue is climbing from our foundational PD-1 inhibitor, we see deal opportunities spanning the portfolio and geographies, and we have two promising pipeline candidates with multiple clinical readouts coming in 2026. Operator, we're ready for questions.

Jay Olson analyst
#8

Congratulations on the advances made. We have a few inquiries regarding LOQTORZI. Could you give us additional detail about how new patient starts compare with returning patients during 2025, and then how you expect that ratio to evolve over the course of 2026? Also, would you be able to discuss how responsive LOQTORZI is to promotion, along with any specifics about the commercial infrastructure investments you intend to make this year, for instance expanding the field force? Then, if I may, I had a follow-up question about tagmo.

Dennis Lanfear executive
#9

Thanks for asking, Jay. I'll have Sameer speak to the topic of new against repeat patients, and then we'll continue. Please go ahead, Sameer.

Sameer Goregaoker executive
#10

Yes. Thanks for asking, Jay. When it comes to patients who are new compared with those already with us, roughly 25% of what we did in 2025 was driven by newcomers, while continuing patients accounted for the remainder. As you pointed out, how might that look going forward? My view is the balance will move somewhat further in the direction of new patients, since we see substantial room to expand there. Those already in our system will continue to serve as a solid foundation for what we do, given that we anticipate treatment length will also keep growing over time.

Dennis Lanfear executive
#11

Sameer, can you address Jay's question regarding the promotional sensitivity of the product?

Sameer Goregaoker executive
#12

Absolutely. When it comes to sensitivity around promotion, LOQTORZI shows a very high degree of it. The reason is that community-based physicians typically handle 10 to 15 distinct kinds of cancer, and LOQTORZI isn't something they encounter often — perhaps just 1 or 2 NPC cases annually. That means they need constant reminders about LOQTORZI and what it offers. Here's the thing: whenever we do share promotional information about LOQTORZI with a doctor, and we walk them through the efficacy data, we nearly always receive full agreement on prescribing LOQTORZI for the right patients. So again, promotion sensitivity is very high, and we believe there's substantial room to fuel additional growth. Does that address what you were asking, Jay?

Jay Olson analyst
#13

Yes, and perhaps any specifics you might give regarding the extra spending on commercial infrastructure would be helpful. Would field force growth be part of that?

Sameer Goregaoker executive
#14

Yes. Roughly a quarter back, we announced a modest enlargement of our field force. In the live sales force, we grew by 15%; at present, we are bringing on approximately 4 inside sales representatives so that our reach extends into tier 2 targets. As stated during my prepared remarks, we are likewise introducing a contract sales force aimed at VA accounts, concentrating on the Veterans Affairs business. That represents the expansion we have carried out in a highly targeted and focused way.

Dennis Lanfear executive
#15

Jay, the second category where we're putting money is our IT systems. Since this condition is so uncommon, our view is that every possible effort must be made to reach the greatest number of patients. In the prior year, we were able to act on roughly 30% to 35% of the alerts from diagnosis codes. During the current year, we have increased that figure to somewhere around 65% to 70%. We've also directed funds toward the display technology used for the sales team's dashboards. On top of that, as Sameer mentioned a moment ago, our inside sales team is likewise arranging and following up on those alerts. I would simply — yes, I'd like to add one final thought. In our view, each of these moves makes sense when you consider the goal of reaching a possible $175 million in annualized sales per year, and we believe it matters that we get there as quickly as we can.

Jay Olson analyst
#16

That’s really useful. If I may squeeze in one more thing about Tagmo, could you discuss whether you have any intentions to look into a triple combination? I’m aware that J&J recently shared phase I combination results involving pasritamig and docetaxel. What’s your thinking on bringing Tagmo into that mix as part of a triple combo for prostate cancer?

Dennis Lanfear executive
#17

Dr. Lavallee?

Theresa Lavallee executive
#18

Yeah. No, I'd say what we're after here is getting the most benefit we can for patients in CRPC. Obviously we're keeping an eye on how those trials turn out. I think the sensible first move is to combine the two drugs and see what effect each one contributes, along with the safety and the efficacy, and then, if that works out, potentially move into earlier lines using other combinations that would be worth pursuing.

Mike Nedelcovych analyst
#19

Two things from me. The first concerns casdozokitug. My understanding is that the frontline HCC study has randomization but no blinding, so I'd like to know whether you are monitoring responses. If you are, does what you're observing increase or decrease your confidence regarding casdozo's prospects? That's question one. Question two has to do with Tagmokitug. A substantial amount of data across multiple tumor types is expected around the middle of this year. So I'm wondering what your approach to sharing those results will be. Should we expect press releases for each indication separately, or a single combined release covering the solid tumor trial? What's your disclosure plan for this data?

Dennis Lanfear executive
#20

Thank you, Mike. I'll hand both of those over to Dr. Dias. Rosh, could you address the casdozo question first, followed by the one about Tagmo data.

Rosh Dias executive
#21

Okay, Mike, I appreciate that question. Regarding your first point about Casdozokitug — clearly, these studies are still running and they're open-label, but since they're ongoing, we'll share results once the data has matured. What I'd point back to is the earlier Atezo Bev Casdozokitug trial. As I laid out in my prepared comments, the top-line findings showed that as time passed, the data matured — the response rate went up and responses became deeper. To repeat, Casdozokitug is an active study, so I have nothing more to say about it right now. Now, on your Tagmokitug question, what you're really asking is how we plan to report those results. Like I mentioned in my prepared remarks, two things really dictate when data becomes available: how many patients there are, and how many scans there are. Those factors will vary across tumor types and across programs. What that boils down to is that predicting the precise timing isn't straightforward, correct? Basically, there are two possibilities. One is that the timing lines up with a congress's submission deadlines; the other is that it doesn't. In the first case, we'll put it out at a congress. In the second case, we'll put it out through corporate disclosure. I'd also point out that we have something of a history of putting data out as soon as it's ready. Take a look at the AACR data from last year — that's roughly our high-level approach.

Colleen Hanley analyst
#22

Thanks for the kind words about our progress. Let's take a follow-up on the casdozo frontline HCC study as a starting point. We understand that those data are going to keep maturing as time goes on, but could you share your perspective on how long that maturation process takes, and of the patients you report in this first readout, how many will fall inside that mature window? At an early readout like this, is there some bar you'd be aiming to clear?

Rosh Dias executive
#23

Yes — let me break that down a bit. Regarding your first question about what we'll be looking for, what we'd really like to do is achieve an overall response rate that beats what was seen before with the current standard of care. As a reminder, that figure was roughly 30% for the Atezo/Bev combination by itself. In our earlier study, the maturation window ran somewhere from 6 to 12 months, correct? So multiple data cuts existed. Across those 3 data cuts spanning that roughly 6-, 9-, 12-month stretch, the response rate went up and the responses got deeper. So that, once again, is essentially what we'd anticipate. As for how many patients and which data we're likely to report, that's somewhat difficult to address precisely, mainly for the reason I gave during my prepared remarks, correct? Two factors are at play. One is how patients get accrued, and the other is how many scans were reported out. We'll keep reporting that out as we learn more. What I can say is that I believe we'll have sufficient patients with sufficient scans to show a signal of early activity around the mid-year timeframe, as we've said before.

Colleen Hanley analyst
#24

Great. That's helpful. And then if you could just kind of walk us through what you're viewing as some of the important updates on the competitive front for CCR8 this year and how that might impact your development strategy going forward?

Dennis Lanfear executive
#25

Thanks for the question, Colleen. Will let Dr. Lavallee address that. Theresa any comments on the competitive dynamic in the CCR expense?

Theresa Lavallee executive
#26

Yeah. I mean, I believe what we're looking for is that the two extremes of additional data being released would be the favorable side and watching news come out about the trials, especially from a few of the major companies that have close to 1,000 patients enrolled in their trial. We'd expect — I mean, what I'd point out regarding BMS is that they, over the past two, JPMorgan have included CCR8 on their launch map by the end of the decade. It's possible we'll see other programs shelved due to problems with the molecule.

Rosh Dias executive
#27

Colleen, there's one more thing I wanted to bring up regarding how much data we have. I realize I've made this point previously, but I'll say it again: our focus isn't solely on ORR. As you know, durability matters, safety matters, and the overall clinical benefit rate matters. What we'll be examining as the program advances is truly that complete picture of the data.

Colleen Hanley analyst
#28

Then for my final question, if I may — congratulations once more on that J&J deal you just completed. When you think about upcoming BD transactions, what do you think would look most appealing for Tagmo? Would you keep things inside the T-cell engager space, or is there something else that would draw your interest most?

Dennis Lanfear executive
#29

Sure — like we said during our prepared remarks, a really intriguing aspect of Tagmokitug, and one that makes it so promising, is how its mechanisms of action could potentially apply broadly across different modalities, including ADCs, T-cell engagers, and radiation. As Dr. Lavallee pointed out when she gave her prepared remarks, many cancer therapies lead to increased Treg generation; our view is that this is quite broad, and I believe our focus will be on striking further arrangements with other companies and finding out what we can accomplish so far this year.

Brian Cheng analyst
#30

Regarding Tagmo specifically, what's the right way to view the plan for building out your prostate cancer combination with Pasri, when it comes to prioritization, since you've already got hands in a number of indications right now?

Theresa Lavallee executive
#31

Yeah. My view is that every one of those studies can be run. What I'd say is that our top priority is truly obtaining the data across those tumor types that have solid scientific justification for elevated target expression alongside varying immune contexts. Given how common CRPC is and how much need exists there, those trials ought to accrue fairly fast, in my view. That could be a really compelling indication to examine. It matters just as much as every other one. What we're genuinely after is the data, so we can learn. As Rosh and I have discussed previously, our program is designed very deliberately to discover the optimal setting for employing Tagmokitug, and at this point not only alongside toripalimab, but together with the T-cell engager as well.

Brian Cheng analyst
#32

When it comes to the bar for mCRPC in this case, what would you hope to observe in this third line plus setting regarding the PSA50 endpoint?

Rosh Dias executive
#33

Yeah. So, a few things I'd mention. As I noted during my prepared remarks, we're going to be evaluating safety along with PSA50, so each of those matters. I won't say much about what we expect at this point, but here's what I can share: if you examine the present treatment landscape for PSA50, it truly declines. There's a sharp drop following the second line, correct? For the first line, it can reach roughly 70%, or as high as 70%, when it comes to PSA50. By the time you reach second line, it sits within the 45% range. Once you're at third line, it's at approximately 20% or below. Those are essentially the existing benchmarks. Beyond that, I won't say anything more until we begin opening up the study, which we expect to happen in the second half of this year.

Dennis Lanfear executive
#34

Brian, my guess is that this is Denny speaking. My guess is that you can expect a bit more commentary regarding this study during the August call, when we will report Q2, since we expect to start it in the year's second half.

Douglas Tsao analyst
#35

Douglas, I believe it was you who mentioned that at roughly $35 million in revenue, the company essentially reaches the point of cash flow breakeven, if you leave out R&D. So how — you noted something to the effect that R&D was discretionary, or rather, not exactly discretionary, but that you had some latitude in deciding where the money goes and how much to spend. Maybe you could walk us through the framework for what you consider a suitable amount of R&D spending, and how you strike that balance between the revenue coming in and possibly requiring extra outside capital to support the R&D program, especially since the range of opportunities open to the company appears to have been growing quite well.

Dennis Lanfear executive
#36

Thanks, Doug. Let me try to lay out how we see things and give you a way to think about the budgeting decisions. First, as I mentioned, with the commercial team, commercial spend covers the commercial team itself, all commercial costs, the computer systems, the IT costs, whatever the sales force requires. Then there are royalties — for instance, a 20% royalty owed to Junshi. There's COGS. I'd describe all of that as the spending needed to generate sales. That comes to roughly $15 million, $16-ish million per quarter. As for the other spending, the $30 million to $35 million, that covers carrying those same commercial costs along with higher COGS from greater sales. It also includes internal SG&A, the remaining headcount at the company, and so forth; basically everything except what I'd call additional development or clinical trial costs. We treat those in a separate bucket, and I'd place them in bucket number 3. So when we began developing the assets after the Biosimilar spin out, we had $250 million, and we were proceeding, and we pinpointed a set of trials we intended to run. What we've done since then, naturally, is broaden that somewhat. We feel it's very strategically valuable to pursue the J&J engagement with prostate; we also believe CRC represents an area of unmet medical need. For now, we feel we're clearly funded for the clinical trials we've completed. As Tagmokitug, as Dr. Lavallee told you, has very broad potential applicability. On the other hand, I think we've demonstrated that we are very judicious and thoughtful with our spending, and we'll keep doing that. We want to grasp the mechanism of action. We want to grasp truly where it works and why it works and put our bets there. I think that on the whole, we've positioned the company well for the future. Since you've known us a long time, we keep a pretty sharp eye on our finances. And finally, considering how we've performed with core during the last couple of years—especially with revenues doubling, '25 compared to '24—that gives us a reasonable amount of confidence we can push it up to $175 million in annualized sales by 2028. And as I mentioned, the milestones along the way include somewhere around $15 million or $16 million, where the commercial team becomes self-funding, and then moving beyond 30-plus, it'll be supporting the remainder of the company. And really, that's Lavori's essential function—to fund all of those things for us so we're able to develop the drugs. And that's the perspective we take on it.

Douglas Tsao analyst
#37

Alright, Denny, that's genuinely useful. Perhaps a quick follow-up aimed at Sameer. What is the length of treatment right now for people receiving LOQTORZI? I believe you kind of suggested that an uptick in the count of newly starting patients was anticipated. I'm simply wondering how large a chance exists for you to observe gains when it comes to the persistence equation?

Sameer Goregaoker executive
#38

Yes. I appreciate the question. Let me first remind everyone that we have 2 categories of indications. There is a frontline indication covering a locally advanced recurrent setting along with the frontline metastatic. In addition, we have second line metastatic as well as third line metastatic indications. Treatment duration for the second line indication ought to be considerably shorter compared with the frontline indication. That is more or less the fundamental premise drawn from the clinical trials. Having said that, we examine therapy duration on a quarterly basis, every 3 months, by reviewing claims data. Each time we review it, the duration of therapy keeps expanding. I'm not yet prepared to provide a figure for the average duration of therapy, since we just don't have sufficient patients and cohorts available to examine an average number. What I can tell you is that the duration keeps rising, and there remains room for improvement between where we stand today and where the clinical trial duration stood. Regarding the other question you hinted at, contributions from existing patients alongside contributions from new patients are both going to keep increasing as we move through the next couple of years.

Operator operator
#39

Thanks. That brings us to the end of today's conference call. We appreciate everyone for joining in. You're welcome to disconnect at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Coherus Oncology, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Coherus Oncology, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.